Literature DB >> 6966652

In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.

I Yron, T A Wood, P J Spiess, S A Rosenberg.   

Abstract

A method has been developed for isolating and growing lymphoid cells infiltrating murine solid tumors. When tumor cell suspensions are placed in T cell growth factor (TCGF) lymphoid cells and not tumor cells proliferate. By 7 to 9 days lymphoid cells free of tumor can be harvested and grown continuously in TCGF. The growth of these cells is dependent on the presence of TCGF but not on the presence of concanavalin-A. Tumor cell suspensions that have been freed of T lymphoid cells by treatment with anti-Thy-1.2 serum and complement or by fractionation on Ficoll gradients exhibit no cell out-growth in TCGF. The lymphoid cells growing in TCGF exhibit significant cytotoxicity for syngeneic tumor cells and normal fibroblasts grown in culture but do no lyse normal lymphoid cells.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6966652

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

1.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

2.  Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.

Authors:  C J Honsik; G Jung; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

3.  Tumor-infiltrating lymphocytes from nonrenal urological malignancies.

Authors:  G P Haas; D Solomon; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 4.  The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.

Authors:  Frank Cichocki; Michael R Verneris; Sarah Cooley; Veronika Bachanova; Claudio G Brunstein; Bruce R Blazar; John Wagner; Heinrich Schlums; Yenan T Bryceson; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Curr Top Microbiol Immunol       Date:  2016       Impact factor: 4.291

Review 5.  IL-2: the first effective immunotherapy for human cancer.

Authors:  Steven A Rosenberg
Journal:  J Immunol       Date:  2014-06-15       Impact factor: 5.422

6.  Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires.

Authors:  B A Fox; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Preferential homing of tumor-infiltrating lymphocytes in tumor-bearing mice.

Authors:  I H Ames; G M Gagne; A M Garcia; P A John; G M Scatorchia; R H Tomar; J G McAfee
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

8.  The development of gene therapy for the treatment of cancer.

Authors:  S A Rosenberg; W F Anderson; M Blaese; P Hwu; J R Yannelli; J C Yang; S L Topalian; D J Schwartzentruber; J S Weber; S E Ettinghausen
Journal:  Ann Surg       Date:  1993-10       Impact factor: 12.969

9.  Cytokine regulation of cell-to-cell interactions in lymphokine-activated killer cell cytotoxicity in vitro.

Authors:  T Takahashi; H Ishikura; K Iwai; C Takahashi; H Kato; T Tanabe; T Yoshiki
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

10.  The tumor microenvironment: the making of a paradigm.

Authors:  Isaac P Witz
Journal:  Cancer Microenviron       Date:  2009-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.